Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.63 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012513 | 0.98 | GSTK1 (0.64) | GSTK1ENPEPFOLH1LMNATSHR | |
| SCHEMBL9253547 | 0.98 | GSTK1 (0.64) | GSTK1ENPEPFOLH1LMNATSHR | |
| SCHEMBL6361383 | 0.98 | GSTK1 (0.64) | GSTK1ENPEPFOLH1LMNATSHR | |
| SCHEMBL2868539 | 0.98 | GSTK1 (0.64) | GSTK1ENPEPFOLH1LMNATSHR | |
| SCHEMBL3018158 | 0.93 | ENPEP (0.59) | GSTK1ENPEPFOLH1LMNATSHR | |
| SCHEMBL15956044 | 0.86 | TSHR (0.60) | GSTK1ENPEPFOLH1LMNATSHR | |
| Dihydrolipoic Acid SCHEMBL867951 | 0.84 | FOLH1 (0.56) | GSTK1ENPEPFOLH1LMNATSHR | |
| Dihydrolipoic Acid SCHEMBL1115003 | 0.84 | FOLH1 (0.56) | GSTK1ENPEPFOLH1LMNATSHR | |
| Dihydrolipoic Acid SCHEMBL618576 | 0.84 | FOLH1 (0.56) | GSTK1ENPEPFOLH1LMNATSHR | |
| Dihydrolipoic Acid SCHEMBL19773 | 0.84 | FOLH1 (0.56) | GSTK1ENPEPFOLH1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050208007-A1 | Composition to permanently reshape the hair containing at least one carboxydithiol | L'OREAL S.A. (FR) | 2005-09-22 | — | — | US | claimed |
| EP-4277636-A1 | MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023198857-A1 | \"GOOD\" BUFFER-BASED CATIONIC LIPIDS | SANOFI (FR) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023178167-A1 | ASYMMETRIC PIPERAZINE-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022155418-A9 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022155418-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2021051172-A1 | LIPID PRODRUGS OF CELECOXIB AND USES THEREOF | MONASH UNIVERSITY (AU) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020251969-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2016077581-A1 | ISOSTEVIOL TRIAZOLES AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2014085791-A2 | COMPOSITIONS AND USES THEREOF FOR TREATING MULTIPLE MYELOMA | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2006086325-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006074351-A2 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | AGENCOURT PERSONAL GENOMICS (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074202-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20050208007-A1 | Composition to permanently reshape the hair containing at least one carboxydithiol | L'OREAL S.A. (FR) | 2005-09-22 | — | — | US | disclosed |
| EP-1558595-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005063258-A1 | KINASE INHIBITOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004096237-A2 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004037801-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050208007-A1 | Composition to permanently reshape the hair containing at least one carboxydithiol | CTH, BHMT2, CRAT | GSTK1 1598/4885ENPEP 564/4885FOLH1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.